Chinese Drug Development Firm Ribo Completes $28M Series C1 Round December 5, 2019

Suzhou Ribo Life Science Co. Ltd. (Ribo), a siRNA drug development company in China, announced today that it has raised RMB203 million (US$28.78 million) in a series C1 round of financing led by Panlin Capital and Trinity Innovation Fund. Legend Capital, SDIC Innovation, Hanyang Capital, Blue Ocean Capital Group, Daxie Yungong Investment, Shenzhen Zhonghui Investment […]

Chinese Drug Development Firm Ribo Completes $28M Series C1 Round comes originally from China Money Network. All Rights Reserved.